Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New bypass device could spare rectal cancer patients from stoma surgery

NCT ID NCT04184973

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This trial tests a temporary bypass device called CG-100 in 250 rectal cancer patients undergoing surgery. The device is placed inside the bowel to protect the surgical connection, potentially reducing the need for a temporary stoma. Researchers will compare stoma rates and complications between patients who get the device and those who receive standard stoma surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CG-100 intraluminal bypass device
What this could lead to
If it works, this device could help many rectal cancer patients avoid a temporary stoma and its associated complications after surgery.
What could go wrong
This is a mid-stage trial with 250 participants, so results may not apply to all patients. The device may not reduce stoma rates as hoped, and there are risks of device-related complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient is willing to comply with protocol-specified follow-up evaluations 2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed. 3. Patient is diagnosed with colorectal cancer 4. Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge 5. Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation. 6. Patient is scheduled to undergo mechanical bowel preparation 7. The patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB). Exclusion Criteria: 1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis) 2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion). 3. Patients with ASA classification \> 3 4. Albumin \< 30 g/liter 5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease 6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression 7. BMI ≥ 40 8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery. 9. The patient is currently participating in another investigational drug or device study unless pre-approved by the sponsor. 10. Patient has been taking regular systemic/ steroid medication in the last 6 months. 11. Patients is taking antimetabolites or antiplatelet agents. 12. Patient has preexisting sphincter problems 13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis. 14. Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT) 15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data 16. Pregnant or nursing female patients. Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asklepios

    RECRUITING

    Hamburg, Germany

  • CHUV

    RECRUITING

    Lausanne, Switzerland

  • Colorado University Anschutz Medical Campus

    RECRUITING

    Aurora, Colorado, 80045, United States

  • Henry Ford Health System

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Humanitas Research Hospital

    RECRUITING

    Milan, Lombardy, 20089, Italy

  • Kaiser Permanente San Diego medical Center

    RECRUITING

    San Diego, California, 92123, United States

  • Lifespan & Brown Surgical Associates

    ACTIVE_NOT_RECRUITING

    Providence, Rhode Island, 02906, United States

  • Soroka University Medical Center

    RECRUITING

    Beersheba, 85025, Israel

  • University of California Irvine

    ACTIVE_NOT_RECRUITING

    Irvine, California, 92868, United States

  • University of Utah Health

    ACTIVE_NOT_RECRUITING

    Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.